Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Saturday, February 24, 2018
 
Recommended for you
GE hires new chief lawyer from Merck
The Business Journals • Greg Ryan
Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid
24/7 Wall St. • Trey Thoelcke
Sangamo, Gilead in cell therapy gene editing deal
Week in Review
Sangamo, Gilead in $3B cell therapy gene editing deal
Week in Review
Gilead Sciences Announces Senior Management Change
BusinessWire
Sangamo Signs Oncology Deal with Gilead's Kite Worth Potentially $3 Billion
Equities.com • Equities Research
Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?
24/7 Wall St. • Jon C. Ogg
Cirrhosis - Pipeline Insight, 2018 by Pipeline Therapeutics, Discovery Stage, Therapeutic Assessment, Inactive Products & Comparative Analysis - ResearchAndMarkets.com
BusinessWire
Meet Gilead and Sangamo’s Next Big Cancer Collaboration
24/7 Wall St. • 247chrislange
East Bay gene editing company snags Gilead deal worth up to $3.2 billion
The Business Journals • Ron Leuty
 
Recommended for You
Corporate Governance, Gilead Sciences
GE hires new chief lawyer from Merck
The Business JournalsGreg Ryan
General Electric Co.’s shuffling of its executive ranks continued Friday, with the company announcing that it is hiring Merck & Co. Inc.’s top lawyer as its new general counsel. The new GC, Michael Holston, will replace Alex Dimitrief, who is moving to...
Share
Cancer, Gilead Sciences
Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid
24/7 Wall St.Trey Thoelcke
The concept behind cancer immunotherapy vaccines has been around since, believe it or not, 1891. This is when one Dr. William Coley began directly injecting tumors with bacteria, with 10% to 20% complete response rates. Since this was nearly 130 years ago,...
Share
Cancer, Gilead Sciences
Sangamo, Gilead in cell therapy gene editing deal
Week in Review
Sangamo Therapeutics Inc. (NASDAQ:SGMO) gained $3.20 (14%) to $25.40 on Thursday after partnering with the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) to use Sangamo's zinc finger nuclease (ZFN) and adeno-associated virus (AAV) technology to develop next-generation autologous and allogeneic...
Share
Biotechnology, Cancer
Sangamo, Gilead in $3B cell therapy gene editing deal
Week in Review
Sangamo Therapeutics Inc. (NASDAQ:SGMO) gained $3.20 (14%) to $25.40 on Thursday after partnering with the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) to use Sangamo's zinc finger nuclease (ZFN) and adeno-associated virus (AAV) technology to develop next-generation autologous and allogeneic...
Share
Corporate Governance, Gilead Sciences
Gilead Sciences Announces Senior Management Change
BusinessWire
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that James Meyers, Executive Vice President, Commercial Operations, will retire. Mr. Meyers joined Gilead in 1996 as a regional sales director and was appointed to his current role in 2016. Following a...
Share
Cancer, Gilead Sciences
Sangamo Signs Oncology Deal with Gilead's Kite Worth Potentially $3 Billion
Equities.comEquities Research
In conjunction with its 2017 year-end update, Sangamo Therapeutics (Nasdaq: SGMO) today announced a collaboration with Kite, a Gilead Sciences (Nasdaq: GILD) company, to use Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in...
Share
Biotechnology, Gilead Sciences
Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?
24/7 Wall St.Jon C. Ogg
When it comes to mid-cap and small-cap biotech stocks, there are two ways shareholders get rewarded ahead of or after big drug development news. One is that the company grows and grows into its own monster, and the other way to rewards...
Share
Gilead Sciences, Novartis AG
Cirrhosis - Pipeline Insight, 2018 by Pipeline Therapeutics, Discovery Stage, Therapeutic Assessment, Inactive Products & Comparative Analysis - ResearchAndMarkets.com
BusinessWire
DUBLIN--(BUSINESS WIRE)--The "Cirrhosis - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. 'Cirrhosis - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cirrhosis development. The report provides detailed coverage...
Share
Cancer, Gilead Sciences
Meet Gilead and Sangamo’s Next Big Cancer Collaboration
24/7 Wall St.247chrislange
Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares saw a solid gain early Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences Inc. (NASDAQ: GILD). Specifically, Kite Pharma is collaborating with Sangamo’s zinc finger...
Share
Gilead Sciences
East Bay gene editing company snags Gilead deal worth up to $3.2 billion
The Business JournalsRon Leuty
Sangamo Therapeutics Inc.'s gene-editing technology is playing second fiddle to CRISPR no longer. The Richmond-based company (NASDAQ: SGMO) Thursday disclosed a deal with Kite, a subsidiary of Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), to develop next-generation cell therapies in cancer. It...
Share